We are proud to announce that CORE-008 has opened Cohort B, this trial is for patients who are high-risk BCG-Exposed NMIBC. If you are interested in participating in this trial, or have an appropriate patient for enrollment, please fill out this questionnaire and an employee of CG Oncology will reach out to you via phone to discuss.
COMPOUND/INDICATION
Cretostimogene Monotherapy
COMPOUND/INDICATION
Cretostimogene Monotherapy
COMPOUND/INDICATION
Cretostimogene Monotherapy
COMPOUND/INDICATION
Cretostimogene Monotherapy
COMPOUND/INDICATION
Cretostimogene Monotherapy
1Patients with carcinoma in situ, with or without high-grade Ta/T1 disease.
2Patients with high-grade Ta/T1. Cohort P is a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval.
Additionally, we’ve initiated an Expanded Access Program for cretostimogene in the US for patients with NMIBC who are unresponsive to BCG and meet certain program eligibility criteria.